{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:59:21Z","timestamp":1761562761748,"version":"3.37.3"},"reference-count":58,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009730","name":"Stand Up To Cancer","doi-asserted-by":"crossref","award":["SU2C-AACR-DT0612"],"award-info":[{"award-number":["SU2C-AACR-DT0612"]}],"id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001634","name":"Gateway for Cancer Research","doi-asserted-by":"publisher","award":["G-12-500"],"award-info":[{"award-number":["G-12-500"]}],"id":[{"id":"10.13039\/100001634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009730","name":"Stand Up To Cancer","doi-asserted-by":"publisher","award":["SU2C-AACR-DT0612"],"award-info":[{"award-number":["SU2C-AACR-DT0612"]}],"id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Although combination BRAF and MEK inhibitors are highly effective for the 40\u201350% of cutaneous metastatic melanomas harboring <jats:italic>BRAF<\/jats:italic><jats:sup>V600<\/jats:sup> mutations, targeted agents have been ineffective for <jats:italic>BRAF<\/jats:italic><jats:sup>V600<\/jats:sup>wild-type (wt) metastatic melanomas. The SU2C Genomics-Enabled Medicine for Melanoma Trial utilized a Simon two-stage optimal design to assess whether comprehensive genomic profiling improves selection of molecular-based therapies for <jats:italic>BRAF<\/jats:italic><jats:sup>V600<\/jats:sup>wt metastatic melanoma patients who had progressed on standard-of-care therapy, which may include immunotherapy. Of the response-evaluable patients, binimetinib was selected for 20 patients randomized to the genomics-enabled arm, and nine were treated on the alternate treatment arm. Response rates for 27 patients treated with targeted recommendations included one (4%) partial response, 18 (67%) with stable disease, and eight (30%) with progressive disease. Post-trial genomic and protein pathway activation mapping identified additional drug classes that may be considered for future studies. Our results highlight the complexity and heterogeneity of metastatic melanomas, as well as how the lack of response in this trial may be associated with limitations including monotherapy drug selection and the dearth of available single and combination molecularly-driven therapies to treat <jats:italic>BRAF<\/jats:italic><jats:sup>V600<\/jats:sup>wt metastatic melanomas.<\/jats:p>","DOI":"10.1371\/journal.pone.0248097","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T17:24:26Z","timestamp":1617816266000},"page":"e0248097","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C\/MRA genomics-enabled clinical trial"],"prefix":"10.1371","volume":"16","author":[{"given":"Patricia M.","family":"LoRusso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandar","family":"Sekulic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A.","family":"Sosman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winnie S.","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Carpten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Craig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David B.","family":"Solit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan H.","family":"Bryce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A.","family":"Kiefer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Aldrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Nasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara A.","family":"Byron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Jo","family":"Pilat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott A.","family":"Boerner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Durecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William P. D.","family":"Hendricks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Enriquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyler","family":"Izatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Keats","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Legendre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetomir N.","family":"Markovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Weise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima","family":"Naveed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gargi D.","family":"Basu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shobana","family":"Sekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Adkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Tassone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthigayini","family":"Sivaprakasam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Zismann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie S.","family":"Calvert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuel F.","family":"Petricoin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie Anne","family":"Fecher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Lao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Paul","family":"Eder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas J.","family":"Vogelzang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Perlmutter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Gorman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Manica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Schork","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Zelterman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"DeVeaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard W.","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Lance","family":"Cowey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0183-4202","authenticated-orcid":true,"given":"Jeffrey M.","family":"Trent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,4,7]]},"reference":[{"key":"pone.0248097.ref001","unstructured":"Noone AM, N. H, M. K, D. M, A. B, M. Y, et al. SEER Cancer Statistics Review, 1975\u20132015, National Cancer Institute Bethesda, MD [https:\/\/seer.cancer.gov\/csr\/1975_2015\/, based on November 7 SEER data submission, posted to the SEER web site, April 8]."},{"issue":"5","key":"pone.0248097.ref002","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1185\/03007995.2015.1021904","article-title":"Overall survival in patients with metastatic melanoma","volume":"31","author":"X Song","year":"2015","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"pone.0248097.ref003","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"FS Hodi","year":"2018","journal-title":"The Lancet Oncology"},{"issue":"19","key":"pone.0248097.ref004","first-page":"30388","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"22","author":"C Robert","year":"2019","journal-title":"Lancet Oncol"},{"issue":"26","key":"pone.0248097.ref005","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"C Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"pone.0248097.ref006","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"377","author":"JD Wolchok","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"pone.0248097.ref007","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"PB Chapman","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0248097.ref008","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"R Dummer","year":"2018","journal-title":"Lancet Oncol"},{"issue":"20","key":"pone.0248097.ref009","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"J Larkin","year":"2014","journal-title":"N Engl J Med"},{"key":"pone.0248097.ref010","unstructured":"Long GV, Stroyakovskiy D Fau\u2014Gogas H, Gogas H Fau\u2014Levchenko E, Levchenko E Fau\u2014de Braud F, de Braud F Fau\u2014Larkin J, Larkin J Fau\u2014Garbe C, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. (1533\u20134406 (Electronic))."},{"issue":"10","key":"pone.0248097.ref011","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"GV Long","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7653","key":"pone.0248097.ref012","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"NK Hayward","year":"2017","journal-title":"Nature"},{"issue":"11","key":"pone.0248097.ref013","doi-asserted-by":"crossref","first-page":"e111153","DOI":"10.1371\/journal.pone.0111153","article-title":"Clonal architectures and driver mutations in metastatic melanomas","volume":"9","author":"L Ding","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"pone.0248097.ref014","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic Classification of Cutaneous Melanoma","volume":"161","year":"2015","journal-title":"Cell"},{"issue":"9","key":"pone.0248097.ref015","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/ng.3361","article-title":"Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas","volume":"47","author":"M Krauthammer","year":"2015","journal-title":"Nat Genet"},{"issue":"2","key":"pone.0248097.ref016","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"E Hodis","year":"2012","journal-title":"Cell"},{"issue":"4","key":"pone.0248097.ref017","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1101\/gr.213348.116","article-title":"Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma","volume":"27","author":"WS Liang","year":"2017","journal-title":"Genome Res"},{"issue":"8","key":"pone.0248097.ref018","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1158\/1535-7163.MCT-15-0153","article-title":"Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C\/MRA Melanoma Dream Team","volume":"14","author":"PM LoRusso","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"pone.0248097.ref019","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(13)70024-X","article-title":"MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study","volume":"14","author":"PA Ascierto","year":"2013","journal-title":"Lancet Oncol"},{"issue":"5","key":"pone.0248097.ref020","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/bjc.2017.10","article-title":"A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1\/2 inhibitor","volume":"116","author":"JC Bendell","year":"2017","journal-title":"Br J Cancer"},{"issue":"6","key":"pone.0248097.ref021","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s00280-016-3019-5","article-title":"A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors","volume":"77","author":"K Watanabe","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7229","key":"pone.0248097.ref022","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nature07586","article-title":"Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi","volume":"457","author":"CD Van Raamsdonk","year":"2009","journal-title":"Nature"},{"issue":"23","key":"pone.0248097.ref023","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1000584","article-title":"Mutations in GNA11 in uveal melanoma","volume":"363","author":"CD Van Raamsdonk","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0248097.ref024","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1038\/s41467-019-11107-x","article-title":"Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets","volume":"10","author":"F Newell","year":"2019","journal-title":"Nat Commun"},{"issue":"7463","key":"pone.0248097.ref025","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"LB Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"13","key":"pone.0248097.ref026","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1158\/1078-0432.CCR-09-0280","article-title":"GAB2 amplifications refine molecular classification of melanoma","volume":"15","author":"KA Chernoff","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"21","key":"pone.0248097.ref027","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1002\/cncr.30258","article-title":"Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies","volume":"122","author":"AP Algazi","year":"2016","journal-title":"Cancer"},{"issue":"23","key":"pone.0248097.ref028","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"A Snyder","year":"2014","journal-title":"N Engl J Med"},{"issue":"6257","key":"pone.0248097.ref029","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"EM Van Allen","year":"2015","journal-title":"Science"},{"issue":"2","key":"pone.0248097.ref030","first-page":"226","article-title":"Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis","volume":"35","author":"SP D\u2019Angelo","year":"2017","journal-title":"Efficacy andJ Clin Oncol"},{"issue":"6","key":"pone.0248097.ref031","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1634\/theoncologist.2014-0468","article-title":"Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review","volume":"20","author":"DB Johnson","year":"2015","journal-title":"Oncologist"},{"issue":"21","key":"pone.0248097.ref032","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1002\/cncr.30259","article-title":"The efficacy of anti-PD-1 agents in acral and mucosal melanoma","volume":"122","author":"AN Shoushtari","year":"2016","journal-title":"Cancer"},{"issue":"1","key":"pone.0248097.ref033","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00262-011-1089-0","article-title":"Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy","volume":"61","author":"R Danielli","year":"2012","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"pone.0248097.ref034","doi-asserted-by":"crossref","first-page":"e0118564","DOI":"10.1371\/journal.pone.0118564","article-title":"Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma","volume":"10","author":"L Zimmer","year":"2015","journal-title":"PLoS One"},{"key":"pone.0248097.ref035","unstructured":"Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. (1474\u20135488 (Electronic))."},{"key":"pone.0248097.ref036","unstructured":"Ren D, Hua Y, Yu B, Ye X, He Z, Li C, et al. Predictive biomarkers and mechanisms underlying resistance to PD1\/PD-L1 blockade cancer immunotherapy. (1476\u20134598 (Electronic))."},{"issue":"3","key":"pone.0248097.ref037","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.cell.2017.01.010","article-title":"Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma","volume":"168","author":"W Hugo","year":"2017","journal-title":"Cell"},{"key":"pone.0248097.ref038","unstructured":"Miao D, Margolis CA-O, Gao WA-O, Voss MA-O, Li WA-O, Martini DJ, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. (1095\u20139203 (Electronic))."},{"key":"pone.0248097.ref039","unstructured":"Trujillo JA-O, Luke JJ, Zha Y, Segal JP, Ritterhouse LL, Spranger S, et al. Secondary resistance to immunotherapy associated with \u03b2-catenin pathway activation or PTEN loss in metastatic melanoma. (2051\u20131426 (Electronic))."},{"key":"pone.0248097.ref040","unstructured":"Liu XA-O, Kong WA-O, Peterson CA-O, McGrail DJ, Hoang A, Zhang X, et al. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. (2041\u20131723 (Electronic))."},{"issue":"19","key":"pone.0248097.ref041","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1200\/JCO.2016.66.6552","article-title":"Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency","volume":"34","author":"E Bouffet","year":"2016","journal-title":"J Clin Oncol"},{"issue":"19","key":"pone.0248097.ref042","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"JR Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"issue":"26","key":"pone.0248097.ref043","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"DT Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"pone.0248097.ref044","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","article-title":"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.","volume":"18","author":"R Dummer","year":"2017","journal-title":"The Lancet Oncology"},{"issue":"1","key":"pone.0248097.ref045","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1158\/1535-7163.MCT-17-0196","article-title":"Ceritinib Enhances the Efficacy of Trametinib in BRAF\/NRAS-Wild-Type Melanoma Cell Lines","volume":"17","author":"D Verduzco","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"15_suppl","key":"pone.0248097.ref046","doi-asserted-by":"crossref","first-page":"9009","DOI":"10.1200\/jco.2014.32.15_suppl.9009","article-title":"A phase 1b\/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity","volume":"32","author":"JA Sosman","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"pone.0248097.ref047","doi-asserted-by":"crossref","first-page":"K9","DOI":"10.1186\/1479-5876-13-S1-K9","article-title":"MEK + CDK4 a regimen for non-BRAF V6000 melanoma","volume":"13","author":"J Sosman","year":"2015","journal-title":"Journal of Translational Medicine"},{"issue":"79","key":"pone.0248097.ref048","doi-asserted-by":"crossref","first-page":"34990","DOI":"10.18632\/oncotarget.26204","article-title":"MEK\/CDK4,6 co-targeting is effective in a subset of NRAS, BRAF and \u2019wild type\u2019 melanomas","volume":"9","author":"C Posch","year":"2018","journal-title":"Oncotarget"},{"key":"pone.0248097.ref049","unstructured":"Kwong LN, Costello Jc Fau\u2014Liu H, Liu H Fau\u2014Jiang S, Jiang S Fau\u2014Helms TL, Helms Tl Fau\u2014Langsdorf AE, Langsdorf Ae Fau\u2014Jakubosky D, et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. (1546-170X (Electronic))."},{"issue":"5","key":"pone.0248097.ref050","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1158\/2159-8290.CD-17-0745","article-title":"Preexisting Rare PIK3CA(E545K) Subpopulation Confers Clinical Resistance to MEK plus CDK4\/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling","volume":"8","author":"G Romano","year":"2018","journal-title":"Cancer Discov"},{"issue":"5","key":"pone.0248097.ref051","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1158\/2159-8290.CD-17-0699","article-title":"In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1\/2-CDK4\/6 Targeting and mTOR-S6 Resistance Mechanisms","volume":"8","author":"JLF Teh","year":"2018","journal-title":"Cancer Discov"},{"key":"pone.0248097.ref052","unstructured":"Jones CL, Holmgren E. An adaptive Simon Two-Stage Design for Phase 2 studies of targeted therapies. (1551\u20137144 (Print))."},{"volume-title":"R: A language and environment for statistical computing","year":"2020","author":"RC Team","key":"pone.0248097.ref053"},{"issue":"11","key":"pone.0248097.ref054","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2004.11.044","article-title":"Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study","volume":"22","author":"SS Agarwala","year":"2004","journal-title":"J Clin Oncol"},{"issue":"9","key":"pone.0248097.ref055","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.1999.17.9.2745","article-title":"Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma","volume":"17","author":"PB Chapman","year":"1999","journal-title":"J Clin Oncol"},{"issue":"11","key":"pone.0248097.ref056","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1093\/annonc\/mdv324","article-title":"A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-na\u00efve patients with metastatic melanoma","volume":"26","author":"EM Hersh","year":"2015","journal-title":"Ann Oncol"},{"issue":"5","key":"pone.0248097.ref057","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1200\/JCO.2012.44.6112","article-title":"Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma","volume":"31","author":"A Ribas","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"pone.0248097.ref058","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/annonc\/mdj138","article-title":"Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG","volume":"17","author":"D Schadendorf","year":"2006","journal-title":"Ann Oncol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0248097","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T17:25:36Z","timestamp":1617816336000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0248097"}},"subtitle":[],"editor":[{"given":"Rui Manuel","family":"Reis","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,4,7]]},"references-count":58,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0248097","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2021,4,7]]}}}